Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anke Eylenbosch
Observed name:
A Eylenbosch
Institution:
Ghent University Hospital
Observed institutions:
Ghent University Hospital,
Ghent University
ORCID:
0009-0004-6342-0923
Observed ORCID:
0009-0004-6342-0923
OpenAlex ID:
A5100028285
From reactive to predictive: Advancing biologic dosing in dermatology
2025
·
Anke Eylenbosch
, Ruoheng Wei
, et al.
·
Journal of the European Academy of Dermatology and Venereology
·
6
One Step Closer to Personalized Dosing of Biologics in Psoriasis
2025
·
Anke Eylenbosch
, Jo L.W. Lambert
·
Journal of Investigative Dermatology
·
3
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial
2026
·
Juul M.P.A. van den Reek
, Charlotte A.M. van Riel
, et al.
·
The Lancet Regional Health - Europe
·
2
Ixekizumab trough concentrations in psoriasis: Paving the way towards personalised therapy: A cohort study
2024
·
Lisa Schots
, Rani Soenen
, et al.
·
JEADV Clinical Practice
·
2
360 Population Pharmacokinetic-pharmacodynamic Model for Secukinumab in Psoriasis Patients
2025
·
A Eylenbosch
, R Soenen
, et al.
·
Journal of Investigative Dermatology
·
1
PDF
O11 Model-informed precision dosing of biologic therapies in psoriasis: development, validation and clinical translation
2026
·
Ruoheng Wei
, Charlotte Thomas
, et al.
·
British Journal of Dermatology
Demographics, Disease Characteristics, and Time to Effective Treatment of Patients with Psoriasis in the Ghent PsoPlus Cohort of 2021
2024
·
Evelyn Meulewaeter
, Anke Eylenbosch
, et al.
·
Dermatology and Therapy
PDF
Show more works
View as search
Works count:
7
Citation count:
14
H-index:
2
I10-index:
Year
Topic
Type